Bio-Techne Expands Oxford Nanopore Partnership to Advance Genetic Testing Solutions
- Bio-Techne expands collaboration with Oxford Nanopore until 2032, enhancing genetic testing solutions and product offerings.
- The partnership focuses on developing targeted enrichment sequencing kits for heritable genetic disorder diagnostics.
- Bio-Techne aims to drive innovation in diagnostics, reinforcing its leadership in the life sciences industry.
Bio-Techne Expands Collaboration with Oxford Nanopore to Enhance Genetic Testing Solutions
Bio-Techne Corporation, a prominent entity in life science tools and diagnostics, significantly broadens its collaboration with Oxford Nanopore Technologies, extending their partnership through 2032. This strategic move comes on the heels of the successful launch of the AmplideX® Nanopore Carrier Plus Kit in March 2025 and strengthens Bio-Techne's commitment to developing a comprehensive portfolio of genetic products. The expanded commercial rights under this agreement enable Bio-Techne to focus on creating targeted enrichment sequencing kits, which are crucial for screening and diagnosing heritable genetic disorders.
Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, articulates the company's dedication to advancing genetic testing solutions that streamline laboratory workflows while providing deeper insights. This collaboration merges Bio-Techne’s diagnostic expertise with Oxford Nanopore's innovative molecular sensing technology, setting the stage for faster, simpler, and more accessible genetic testing. Such advancements are essential as the demand for effective diagnostic solutions continues to rise, particularly in the context of public health and personalized medicine.
The partnership is poised to drive significant innovation in the diagnostics sector. By leveraging Oxford Nanopore’s cutting-edge technology, Bio-Techne aims to enhance its product offerings, ultimately creating a robust foundation for a future portfolio that addresses the evolving needs of laboratories globally. This expansion not only reflects Bio-Techne's strategic vision but also positions the company as a key player in the life sciences industry, where precision and efficiency in genetic testing are paramount.
In the fiscal year 2025, Bio-Techne reports over $1.2 billion in net sales and employs around 3,100 individuals worldwide, underscoring its substantial footprint in the life sciences sector. This enhanced collaboration with Oxford Nanopore is expected to further solidify Bio-Techne's leadership in the diagnostics field.
With this strategic partnership, Bio-Techne is well-equipped to tackle the increasing global demand for advanced genetic testing solutions. The company encourages stakeholders and interested parties to explore more about its offerings through its official website and social media channels.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…